Prudential Financial
MRSN

Prudential Financial’s Mersana Therapeutics MRSN Stock Holding History

Prudential Financial’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-596
Closed -$4.4K – 2493
2025
Q2 		$4.4K Sell
596
-1,865
-76% -$16.4K ﹤0.01% 2424
2025
Q1 		$21.2K Buy
+2,461
New +$38K ﹤0.01% 2252
2024
Q3 		– Sell
-693
Closed -$34.8K – 2768
2024
Q2 		$34.8K Hold
693
– – ﹤0.01% 2648
2024
Q1 		$77.7K Buy
+693
New +$68.9K ﹤0.01% 2552
2023
Q2 		– Sell
-2,046
Closed -$210K – 2670
2023
Q1 		$210K Sell
2,046
-302
-13% -$42.4K ﹤0.01% 2387
2022
Q4 		$344K Sell
2,348
-1,762
-43% -$298K ﹤0.01% 2195
2022
Q3 		$694K Buy
4,110
+2,522
+159% +$410K ﹤0.01% 1923
2022
Q2 		$183K Buy
+1,588
New +$149K ﹤0.01% 2480
2020
Q1 		– Sell
-408
Closed -$58K – 2411
2019
Q4 		$58K Buy
+408
New +$29.8K ﹤0.01% 2394

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prudential Financial's MRSN Position: Q3 2025 in Review

Prudential Financial sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 596 shares — an estimated $4.4K sold.

Prudential Financial first reported a position in MRSN in Q4 2019 and held it in 9 quarters. The position peaked at $694K in Q3 2022. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • Prudential Financial reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Prudential Financial sold 596 Mersana Therapeutics shares in Q3 2025, an estimated $4.4K.
  • Prudential Financial first reported a position in Mersana Therapeutics in Q4 2019 and held it in 9 quarters.
  • Prudential Financial's Mersana Therapeutics position peaked at $694K in Q3 2022.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on Prudential Financial's 13F filing for Q3 2025, filed 13 Nov 2025.